ATAI Life Sciences N.V. Stock News

AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has completed the redomiciliation of its parent company from the Netherlands to the United States, with the new entity incorporated in Delaware. The move was approved by approximately 99% of the votes cast at the company's extraordinary general meeting of shareholders held on November 4.

AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that its common stock has been added to the Nasdaq Biotechnology Index (NBI), effective prior to the market open on December 22. The NBI is designed to track the performance of biotechnology and pharmaceutical companies listed on the Nasdaq Stock Market that meet specific eligibility criteria, including minimum market capitalization, average dai...

NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced its common stock has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prio...

AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that the US Patent and Trademark Office has granted a new patent covering EMP-01, its oral R-MDMA formulation. The company said that the patent includes claims to the drug substance of EMP-01 and is expected to provide exclusivity through 2043.

– Co-Founder Maximilian Martin Appointed CEO – – Co-Founder Christian Angermayer Appointed Executive Chairman – – Jim Murren to join Board of Directors – – Company Appoints Sid Banthiya Chief Financial Officer; Promotes Alex Lopez to Chief Brand Officer and Rick Adams to Chief Sporting Officer – – Names Chris Jones Chief Communications Officer – NEW YORK , Nov. 19, 2025 /PRNewswire/ -- Enhanced...

AtaiBeckley NV (NASDAQ:ATAI, ETR:9VC) reported continued clinical and operational progress during the third quarter of 2025, advancing multiple programs targeting treatment-resistant depression (TRD) and other mental health conditions. During the quarter, the company's lead candidate BPL-003, a mebufotenin (5-MeO-DMT) benzoate nasal spray, was granted Breakthrough Therapy designation by the US ...

AtaiBeckley NV (NASDAQ:ATAI, ETR:9VC) is gaining analyst attention after Phase 2b results for its investigational therapy BPL-003 demonstrated rapid, meaningful, and durable antidepressant effects in treatment-resistant depression (TRD), reinforcing its potential as a differentiated psychedelic therapy. Jefferies highlighted that the data could influence dosing strategies and commercial positio...

Atai Beckley N.V. ( ATAI ) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression November 10, 2025 8:00 AM EST Company Participants Ashleigh Barreto Srinivas Rao - Co-Founder, CEO & Executive Director Kevin Craig - Chief Medical Officer Robert Conley - Chief Research & Development Officer Conference Call Participants Lin Tsai - Jefferies LLC, Research ...